dipyridamole has been researched along with Inner Ear Disease in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borasi, G | 1 |
| Pallestrini, EA | 1 |
| Sperati, G | 1 |
1 other study available for dipyridamole and Inner Ear Disease
| Article | Year |
|---|---|
[The use of platelet aggregation-inhibiting drugs in central vestibular pathology caused by atherosclerotic vascular diseases].
Topics: Aspirin; Dipyridamole; Drug Evaluation; Humans; Intracranial Arteriosclerosis; Labyrinth Diseases; O | 1975 |